Inactive Instrument

Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Biotechnology & Medical Research

Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 08, 2022 at 04:32 pm EST

Albireo Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 9.83 million compared to USD 3.66 million a year ago. Net loss was USD 37.8 million compared to net income of USD 57.09 million a year ago. Basic loss per share from continuing operations was USD 1.92 compared to basic earnings per share from continuing operations of USD 2.96 a year ago. Diluted loss per share from continuing operations was USD 1.92 compared to diluted earnings per share from continuing operations of USD 2.9 a year ago.
For the nine months, revenue was USD 24.87 million compared to USD 8.06 million a year ago. Net loss was USD 120.18 million compared to USD 23.07 million a year ago. Basic loss per share from continuing operations was USD 6.15 compared to USD 1.2 a year ago. Diluted loss per share from continuing operations was USD 6.15 compared to USD 1.2 a year ago.

Latest news about Albireo Pharma, Inc.

CAC40: in green, gains over 2% on a weekly basis	23-03-03	CF
CAC40: PMI and ISM data point to 22nd week of gains	23-03-03	CF
CAC40: 7350 in sight if rates continue to ease	23-03-03	CF
CAC40: breaks through 7300 pts after Bostic's comments	23-03-03	CF
Ipsen: acquisition of Albireo Pharma finalized	23-03-03	CF
French Drugmaker Ipsen Concludes Albireo Pharma Takeover	23-03-02	MT
Albireo Pharma, Inc. Announces Board Changes	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	23-03-02	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	23-02-28	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	23-02-22	MT
Ipsen: extension of the deadline for its tender offer for Albireo Pharma	23-02-22	CF
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment	23-02-14	MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome	23-02-14	DJ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	23-02-14	CI
Insider Sell: Albireo Pharma	23-01-20	MT
Guggenheim Downgrades Albireo Pharma to Neutral From Buy	23-01-11	MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	23-01-11	MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	23-01-11	MT
North American Morning Briefing : Stock Futures -2-	23-01-11	DJ
Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	23-01-10	MT
HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	23-01-10	MT
North American Morning Briefing : More Hawkish Fed -2-	23-01-10	DJ
Top Midday Gainers	23-01-09	MT

Chart Albireo Pharma, Inc.

Duration

Period

More charts

Company Profile

Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	108B
REGENERON PHARMACEUTICALS, INC.	+10.87%	104B
ARGENX SE	+1.28%	22.33B
BIONTECH SE	-13.14%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-10.66%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	14.05B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.51B

Bio Therapeutic Drugs